regulatory
confidence high
sentiment positive
materiality 0.80
Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance
Personalis, Inc.
- CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.
- Reimbursement rate $3,878 for NeXT Personal Dx Breast MRD test; $1,158 for NeXT Personal Single Plasma Test.
- Coverage effective retroactively from October 7, 2025; Single Plasma test available up to 6 years post-treatment.
- Dx Breast MRD test covered once per cancer diagnosis; expands market access for Personalis.